Skip to content
All Sections
Subscribe Now
63°F
Sunday, October 20th 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Morning Report in your inbox!
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Morning Report in your inbox!
Sign Up
Subscribe
Search
Silicon Valley
63°F
Sunday, October 20th 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Organovo, Inc.
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
July 16, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
May 21, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
May 14, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
May 08, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
April 15, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
January 25, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
January 09, 2024
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
December 06, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
CORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 13, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Highlights FXR314 Combination Therapy Potential and Plan
November 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo to Participate in the H.C. Wainwright Global Investment Conference
September 08, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
August 23, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Announces FXR Program
March 21, 2023
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
November 15, 2022
From
Organovo, Inc.
Via
GlobeNewswire
Tickers
ONVO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close